Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →Emcure Pharmaceuticals Limited — Q3 FY26
Emcure delivered a strong Q3 FY26 with revenue of ₹2,363 crore (+20.4% YoY) and EBITDA margin expansion of 110 bps to 19.5%, driven by operating leverage and productivity gains.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Emcure delivered a strong Q3 FY26 with revenue of ₹2,363 crore (+20.4% YoY) and EBITDA margin expansion of 110 bps to 19.5%, driven by operating leverage and productivity gains. Domestic business grew 15% YoY to ₹1,025 crore, led by chronic therapies (cardio, diabetes) and the in-licensed Sanofi portfolio. International revenue rose 24.5% YoY to ₹1,338 crore, with Europe surging 29.6% on Amphotericin B launches and the Mantra acquisition. PAT grew 48% YoY to ₹231 crore (adjusted +65% excluding one-time labor code charge). Management guided for low-to-mid teens revenue CAGR and 300-400 bps EBITDA margin expansion over 3-5 years, supported by the Novo Nordisk semaglutide partnership (Pistra), a strong biosimilar pipeline, and lenacapavir potential. Key risk: delays in key product launches or regulatory hiccups could disrupt the growth trajectory.
एमक्योर की तीसरी तिमाही (अक्टूबर-दिसंबर 2025) की कमाई बहुत अच्छी रही। कंपनी ने ₹2,363 करोड़ का कारोबार किया, जो पिछले साल से 20.4% ज्यादा है। मुनाफा बढ़ाने की क्षमता (EBITDA मार्जिन) 19.5% हो गई, जो पहले से 1.1% ज्यादा है। भारत में बिक्री 15% बढ़कर ₹1,025 करोड़ हुई, खासकर दिल और डायबिटीज की दवाओं से। विदेशों में बिक्री 24.5% बढ़ी, यूरोप में 29.6% का उछाल आया। कंपनी का शुद्ध मुनाफा 48% बढ़कर ₹231 करोड़ हुआ। आने वाले 3-5 सालों में कंपनी को हर साल 12-15% तक बढ़ने और मुनाफा और बेहतर करने की उम्मीद है। हालांकि, नई दवाओं के लॉन्च में देरी या नियमों में अड़चन से यह रफ्तार धीमी हो सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Product launch delays or regulatory hiccups
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Domestic Business Growth
15% YoY
+15% YoY
Domestic revenue grew 15.4% YoY to ₹1,025 crore, driven by chronic therapies and in-licensed portfolio.
Europe Revenue Growth
29.6% YoY
+29.6% YoY
Europe revenue reached ₹464 crore, led by base business growth, Amphotericin B launches, and Mantra acquisition.
MR Productivity
7.0
+0.9 YoY
MR productivity improved from 6.1 in Q3 FY25 to 7.0, with higher productivity in chronic and women's health.
Net Debt
₹1,123 crore
+₹350 crore (expected earnout)
Net debt stood at ₹1,123 crore; expected to rise to ~₹1,500 crore after earnout payment in May 2026, then reduce over 24-36 months.
What Changed vs Last Quarter
NEW
Revenue growth of low-to-mid teens CAGR over 3-5 years
Management aspires for a low-to-mid teens compounded revenue growth rate, driven by domestic outperformance and international expansion.
NEW
Net debt to be zero by end FY28
With strong cash flow generation, management expects to be net debt free by end FY28, barring any acquisitions.
NEW
Capex of ₹350-400 crore per year for next 2-3 years
Annual capital expenditure is expected to remain in the range of ₹350-400 crore, excluding acquisitions.
UPDATED
EBITDA margin expansion of 300-400 bps over 3-5 years
Management expects ~100 bps annual EBITDA margin improvement, targeting 23-24% over 3-4 years organically.
DROPPED
5-year EBITDA margin target of 23-24%
Over the next 4-5 years, EBITDA margins are expected to improve by 300-400 bps from current ~20% levels.
DROPPED
Annual capex of ~₹350 crore
Capex spending guided at ~₹350 crore per annum, with ~₹150 crore for maintenance and ~₹200 crore for capacity/product-specific investments.
DROPPED
Sanofi diabetes portfolio to add ~₹200 crore annualized revenue
The acquired oral diabetes portfolio from Sanofi (brands Emeril and Pain) is expected to contribute ~₹200 crore on an annualized basis, with ~8 months of revenue in FY26.
NEW RISK
Product launch delays or regulatory hiccups
Delays in key product launches (e.g., Amphotericin B in Europe, lenacapavir) or regulatory issues could disrupt growth guidance.
NEW RISK
Gross margin pressure from mix shift
Faster international growth and in-licensed portfolios (Sanofi, semaglutide) are diluting gross margins, which could persist if mix continues.
NEW RISK
Competition in semaglutide and Amphotericin B
Fierce competition expected in GLP-1 and liposomal Amphotericin B markets; management acknowledges eventual competition but cites first-mover advantage.
NEW RISK
Geopolitical/macro risks
Geopolitical disturbances or macro headwinds could impact international operations, though management notes limited US exposure.
RISK GONE
Global HIV funding cuts may impact ARV tender business
Management noted that US contributions to the Global Fund have been reduced, and PEPFAR funding is under pressure, which could affect ARV tender volumes in emerging markets.
RISK GONE
FCM institutional segment pricing pressure
Analyst raised that the FCM (ferric carboxymaltose) institutional segment faces pricing competition from lower-priced rivals, which could drag overall domestic growth.
RISK GONE
Debt reduction timeline may extend due to recent M&A
Management indicated that recent acquisitions (Banks portfolio, Zuventus minority stake) will add to gross debt, pushing the timeline to near-zero debt by 1-1.5 years beyond FY26.
RISK GONE
Semaglutide filing timeline uncertainty
While management confirmed filing batches for Canada this month, the exact approval timeline remains uncertain, and India launch depends on regulatory review.
Fast read
Guidance and risk preview
Management aspires for a low-to-mid teens compounded revenue growth rate, driven by domestic outperformance and international expansion.
Delays in key product launches (e.g., Amphotericin B in Europe, lenacapavir) or regulatory issues could disrupt growth guidance.
View Risks →